Hims & Hers rises 5.37% as CMO appointment fuels rebound
Hims & Hers Health Inc shares rose 5.37% to $31.77 on Tuesday, extending a rebound fueled by the appointment of Anant Vinjamoori as chief medical officer and a broader market rally following a U.S.-Iran peace agreement. The stock is trading above its 20-day, 50-day, and 100-day SMAs but remains below the 200-day SMA, indicating a continued repair phase. The company aims to leverage its strengthened medical leadership to drive longer-duration customer relationships.
*this image is generated using AI for illustrative purposes only.
Hims & Hers Health Inc shares rose 5.37% to $31.77 on Tuesday, continuing a rebound from recent profit-taking following the appointment of a new chief medical officer. The recovery is supported by a broader market rally, as U.S. equities surged following a peace agreement between the United States and Iran that reopened the Strait of Hormuz shipping lane. Despite the gains, the stock remains in a longer-term repair phase, trading below its 200-day simple moving average (SMA) after a steep drawdown.
The company named Anant Vinjamoori as chief medical officer, highlighting his background in longevity medicine and preventive healthcare. The appointment strengthens the medical leadership bench, which now boasts more than 100 years of combined experience across weight loss, sexual health, hormone health, mental health, dermatology, and primary care. This strategic move aims to expand beyond episodic treatment into longer-duration customer relationships, where clinical credibility supports retention and expansion.
Technical Indicators and Key Levels
From a technical perspective, Hims & Hers is in "repair" mode. The stock is currently trading above its 20-day SMA ($26.14), 50-day SMA ($25.85), and 100-day SMA ($23.50). However, the persistence of a "death cross" established in December 2025, where the 50-day SMA fell below the 200-day SMA, keeps the broader bias cautious until longer-term averages are reclaimed.
Momentum is improving, with the Moving Average Convergence Divergence (MACD) above its signal line and a positive histogram, indicating easing downside pressure. Key resistance for the stock is identified at the $32.00 level, which aligns just below the 200-day SMA zone of $33.50, while key support sits at $30.00.
| Metric | Value |
|---|---|
| Current Price | $31.77 |
| 20-day SMA | $26.14 |
| 50-day SMA | $25.85 |
| 100-day SMA | $23.50 |
| 200-day SMA | $33.50 |
| Key Resistance | $32.00 |
| Key Support | $30.00 |
Company Overview
Hims & Hers, launched in 2017, operates a telehealth platform connecting patients with healthcare providers for conditions such as erectile dysfunction, hair loss, skin care, mental health, and weight loss. The platform offers generic, branded, and compounded prescription drugs, alongside over-the-counter medicines, cosmetics, and supplements. The company serves more than 2 million subscribers across all 50 states and select European markets, relying on direct-to-consumer payments rather than insurance.
How will the new chief medical officer's focus on longevity medicine influence Hims & Hers' product pipeline and service offerings over the next year?
Can the stock sustain its current momentum to reclaim the 200-day SMA, or will the 'death cross' signal continue to suppress longer-term bullish sentiment?
What specific metrics will indicate success in the company's strategic shift from episodic treatments to longer-duration customer relationships?
15
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
